Tolterodine Tartrate

Indications and usage: Tolterodine tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

CLINICAL PHARMACOLOGY Tolterodine is a competitive muscarinic receptor antagonist. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. After oral administration, tolterodine is metabolized in the liver, resulting in the formation of the 5-hydroxymethyl derivative, a major pharmacologically active metabolite. The 5-hydroxymethyl metabolite, which exhibits an antimuscarinic activity similar to that of tolterodine, contributes significantly to the therapeutic effect.

With Approximately 9–13 hours terminal plasma half-life for Tolterodine Tartrate residence kinetics and Estimated 79%–91% oral systemic absorption for Tolterodine Tartrate bioavailability, Tolterodine Tartrate undergoes hepatic oxidation via cyp3a4 followed by renal and biliary excretion of tolterodine tartrate metabolites and establishes therapeutic activity over peak plasma concentration (tmax) reached 1–3 hours post-dose for tolterodine tartrate.

Standard adult regimens span 2 mg/1 Tablet, Film Coated, 2 mg/1 Capsule, Extended Release, 4 mg/1 Capsule, Extended Release, 1 mg/1 Tablet, Film Coated, 2 mg/1 Tablet. Prescribers screen specifically against contraindications tolterodine tablets are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma.; known hypersensitivity to tolterodine tartrate or structurally related cholinergic muscarinic antagonist compounds, while community micro-logs most frequently note nausea (8.1% of reports), headache (8% of reports), dizziness (6.6% of reports).